AT&T Inc
Change company Symbol lookup
Select an option...
T AT&T Inc
AICAF Air China Ltd
XOM Exxon Mobil Corp
JNJ Johnson & Johnson
TIP iShares TIPS Bond ETF
OCUL Ocular Therapeutix Inc
NLY Annaly Capital Management Inc
APM Aptorum Group Ltd
ABBV Abbvie Inc

Communication Services : Diversified Telecommunication Services | Large Cap Value
Company profile

AT&T Inc. is a holding company. The Company is a provider of telecommunications, media and technology services globally. The Company operates through four segments: Communication segment, WarnerMedia segment, Latin America segment and Xandr segment. The Communications segment provides wireless and wireline telecom, video and broadband services to consumers.The business units of the Communication segment includes Mobility, Entertainment Group and Business Wireline. The WarnerMedia segment develops, produces and distributes feature films, television, gaming and other content over various physical and digital formats. The business units of the WarnerMedia segment includes Turner, Home Box Office and Warner Bros. Latin America segment provides entertainment services in Latin America and wireless services in Mexico. Viro and Mexico are the business units of the Latin America segment. The Xandr segment provides advertising services.

Day's Change
-0.07 (-0.25%)
B/A Size
Day's High
Day's Low

Today's volume of 18,209,454 shares is on pace to be much lighter than T's 10-day average volume of 35,121,795 shares.


UPDATE: Gilead says coronavirus drug remdesivir can reduce risk of death, but analysts need more proof

10:26 am ET July 11, 2020 (MarketWatch)

By Jaimy Lee

The drugmaker is making 'a confusing suggestion' that remdesivir can demonstrate a survival benefit, according to a Raymond James analyst

Shares of Gilead Sciences Inc. gained 2.0% on Friday after the drugmaker shared potentially promising data about remdesivir that indicates the experimental COVID-19 drug may reduce deaths, though it noted the findings need to be confirmed.

Gilead's (GILD)new analysis ( pairs data from two sources: a comparative, pre-planned analysis of 312 severely ill participants in a randomized, open-label Phase 3 trial, cobbled together with a real-world retrospective cohort of 818 patients who had similar clinical attributes to those included in the trial and had received remdesivir as part of their treatment. It indicates that remdesivir can reduce the risk of mortality in COVID-19 patients by 62%, when compared with the standard of care.

"This is very encouraging but needs to be confirmed in a prospective trial," Scott Gottlieb, the former commissioner of the Food and Drug Administration (FDA), tweeted.

Gilead agreed, saying the new findings require "confirmation in prospective clinical trials" although the company did not say whether it plans to conduct those studies.

Read:Why virus stocks are driving market volatility (

The source for the analysis, however, is unorthodox. It's not from a randomized, placebo-controlled clinical trial, which has long been considered the gold standard for medical research in the U.S., and it compares clinical trial data to non-clinical trial data. "They highlight comparison to non-trial patient group," Bernstein analyst Ronny Gal said in an email. "This is usually not done. However, given the epidemic, it is logical."

This is the latest example of how the coronavirus pandemic has upended the way clinical research is disseminated ( to investors and the public. Some companies are releasing snippets of data rather than full peer-reviewed data sets, and investors are making choices based on preliminary research published in preprint format, rather than waiting for peer-reviewed results.

Gilead acknowledged the shift in how it is sharing clinical information.

"To address the urgency of the continuing pandemic, we are sharing data with the research community as quickly as possible with the goal of providing transparent and timely updates on new developments with remdesivir," Dr. Merdad Parsey, Gilead's chief medical officer, said in a news release.

There have been three major clinical trials for remdesivir so far in the U.S.: a Gilead-sponsored open-label study for moderately ill patients, which found no statistically significant benefit; the Gilead-sponsored Phase 3 trial for severely ill patients that is mentioned above, which was used to help understand the number of days a patient should undergo treatment; and a National Institute of Allergy and Infectious Diseases randomized, controlled study, which found the drug helped reduce the number of a days it takes for a severely ill patient to recover.

A pair of closely watched double-blind, randomized, controlled trials in China were halted early due to enrollment issues but a study published in The Lancet about the multi-site trial in China did not indicate a mortality benefit (

"It is a confusing suggestion given three prospective [randomized, controlled trials] already failed to demonstrate a survival benefit," Raymond James analyst Steven Seedhouse told investors on Friday. "The aggregate clinical data still pretty clearly point to an inconclusive impact on survival at best."

See also:After months of speculation, investors get excited about Pfizer, BioNTech's coronavirus vaccine candidate (

The FDA in May granted an emergency use authorization ( to Gilead for remdesivir in some hospitalized, severely ill patients. The drugmaker said it would work on trials for pregnant women and children ( with COVID-19 as well as for an inhaled version ( of the drug.

Gilead's stock has gained 17.5% year-to-date, with the share price reaching a year-to-date high of $84.00 on April 30, the day after the company released data from the NIAID trial and its own study of severely ill patients. The S&P 500 is down 2.4%.

-Jaimy Lee; 415-439-6400;

(END) Dow Jones Newswires

July 11, 2020 10:26 ET (14:26 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.